Effect of a novel adsorbent on cytokine responsiveness to uremic plasma.

BACKGROUND: Middle molecules such as beta2-microglobulin (beta2M) and advanced glycation end products (AGE)-modified proteins contribute to inflammation in uremia. The BetaSorb column is a new adsorptive device, which contains copolymeric beads, suitable for removal of beta2M and other middle molecules. We assessed the effect of this column on the bioreactivity of uremic plasma, as measured by cytokine responsiveness. METHODS: Uremic plasma was perfused in vitro through the column (10 mL/min) and samples were collected after 10 to 30 passes. Endotoxin-stimulated tumor necrosis factor-alpha (TNF-alpha) and interleukin-10 (IL-10) production by THP-1-derived monocytes was measured following brief exposure to uremic plasma. beta2M levels were measured. The contribution of AGE-modified proteins to the bioreactivity of uremic plasma was explored. RESULTS: TNF-alpha and IL-10 production markedly decreased after 30 passes (629 +/- 78 vs. 144 +/- 62 pg/mL; 207 +/- 25 vs. 117 +/- 23 pg/mL; P=0.04). The column removed beta2M efficiently with a marked decline in plasma levels by 99% after 30 passes. Neutralization of AGE receptor (RAGE) resulted in a further reduction in the bioreactivity of uremic plasma. This was observed with nonperfused, as well as perfused, uremic plasma, suggesting that AGE-modified proteins were biologically active and still present after perfusion. CONCLUSION: The sorbent beads removed uremic solute(s) that prime monocytes to enhanced cytokine production. Removal of beta2M was efficient, and of native and AGE-modified middle molecules likely.

Sorbents in acute renal failure and the systemic inflammatory response syndrome.

Renal replacement therapy in acute renal failure is currently focused on the use of modifications of dialysis (continuous arteriovenous hemofiltration and hemodiafiltration) to remove middle molecular weight toxins, consisting of small proteins, and cytokines involved in the systemic inflammatory response syndrome (SIRS). Conventional high-flux dialyzers are not efficient at removing these molecules, prompting the investigation of sorbents to augment or replace dialysis. Sorbents have been developed to modulate SIRS by targeting cytokines such as IL-1, IL-6, IL-10, IL-18 and TNF, among others. Extensive pre-clinical studies are underway to demonstrate the clinical utility and safety of either adding sorbent hemoadsorption devices to hemodialysis, or the use of such devices alone in SIRS, sepsis, acute renal failure, cardiopulmonary bypass and end-stage renal disease.

Face lifts with hidden scars: the vertical U incision.

The authors present their latest development of a strictly vertical retroauricular incision to minimize a sequela of a face lift, namely, a visible scar. The temporal preauricular vertical incision and the retroauricular vertical incision form two parallel arms of a U-shaped incision. Anteriorly, a downward rotation flap is made to maintain the horizontal temporal line at the right level, and posteriorly, the scalp is incised vertically, followed by extensive superficial retroauricular undermining. In both temporal and retroauricular areas, skin and scalp undergo a redistribution rather than resection, which is extremely limited. The authors' experience with 100 patients who were operated on with vertical U incisions since April of 2000 is described. A total of 35 patients were evaluated after a 6-month follow-up by using clinical and photographic examinations. There were very few complications because the extensive retroauricular flap has good viability. There were no problems with sensitivity, hair loss, or scar spreading, and the hairline was not displaced. The quality of the scar was excellent in the majority of cases. We experienced only a few hypertrophic but well-hidden scars. This approach can also be used in secondary cases when the primary scar is of good quality. The neck pull is as effective as that in the classic approach with a traverse retroauricular incision. The nondetectability of the retroauricular scar is of special interest in young patients and in men. The authors believe there is no contraindication for this technique. It does not significantly prolong the operating time. It includes a large undermining in the retroauricular area (6 cm from the sulcus), but this dissection is easily performed in the superficial plane. In addition to using fibrin glue in the undermined areas, the authors drain the neck. They do not use dressings. Recovery was fast, and there were only two instances of hematomas and two instances of subcutaneous cervical fluid collections in which patients required treatment.

The next step from high-flux dialysis: application of sorbent technology.

The current foci of renal replacement therapy with dialysis are middle molecular weight toxins, consisting of small proteins, polypeptides and products of glycosylation and lipoxygenation. Conventional high-flux dialysis is not efficient at removing these molecules, explaining the increased interest in using sorbents to supplement dialysis techniques. Prototype biocompatible sorbents have been developed and investigated for middle molecule removal; these have been shown, in man, to remove beta(2)-microglobulin, angiogenin, leptin, cytokines and other molecules, without reducing platelets and leukocytes. Extensive clinical studies are underway to demonstrate the clinical utility and safety of adding routinely a sorbent hemoperfusion device to hemodialysis.